- Confirmation of effects compared to global late-stage clinical
trials
- Accelerating the development of obesity treatment through early
licensing out, global joint clinical trials, research funding
investment, etc.
SEOUL,
South Korea, July 18,
2024 /PRNewswire/ -- DX&VX, which is gaining attention for
developing an oral GLP-1 obesity treatment. The company is
accelerating the optimization of new drug candidates.
GLP-1 (glucagon-like peptide-1), an
oral obesity treatment drug being developed by DX&VX, is a
hormone that induces weight loss by suppressing appetite and
increasing satiety to treat obesity.
DX&VX researchers have developed organic compounds that can
be taken orally once a day instead of through injections.
While obesity treatment drug developers are conducting clinical
trials for new oral GLP-1 organic compound drugs, the importance of
this field is expanding day by day.
To date, DX&VX has secured excellent candidate substances
based on its AI-based innovative new drug design technology, and
plans to submit patents for at least two more substances within
this year.
This research outcome is receiving significant attention from
the industry and many pharmaceutical companies, both domestically
and internationally, with some companies exploring the possibility
of cooperation with DX&VX.
Based on these achievements, DX&VX is expected to further
accelerate the development of oral GLP-1 obesity treatments by
utilizing various options such as early licensing out, global joint
clinical trials, and research funding investment. As additional
research results and patent applications continue, the obesity
treatment drug being developed by DX&VX is expected to have
stronger market competitiveness in the future.
A DX&VX official said, "The current research results and
development progress are important achievements that prove the
possibility of an oral obesity treatment with the safe and powerful
effects that the market needs." He added, "We will continue to
develop innovative treatments through continuous research and
development, aiming for early commercialization and showcasing our
results at international academic conferences."
View original
content:https://www.prnewswire.com/news-releases/dxvx-is-on-track-and-accelerating-the-development-of-oral-obesity-treatment-302200601.html
SOURCE Dx&Vx